GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DiaMedica Therapeutics Inc (NAS:DMAC) » Definitions » Net Intangibles Purchase And Sale

DiaMedica Therapeutics (DiaMedica Therapeutics) Net Intangibles Purchase And Sale : $0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is DiaMedica Therapeutics Net Intangibles Purchase And Sale?

Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

DiaMedica Therapeutics's net Intangibles purchase and sale for the three months ended in Dec. 2023 was $0.00 Mil. Its net Intangibles purchase and sale for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

DiaMedica Therapeutics Net Intangibles Purchase And Sale Historical Data

The historical data trend for DiaMedica Therapeutics's Net Intangibles Purchase And Sale can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DiaMedica Therapeutics Net Intangibles Purchase And Sale Chart

DiaMedica Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Intangibles Purchase And Sale
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

DiaMedica Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Intangibles Purchase And Sale Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

DiaMedica Therapeutics Net Intangibles Purchase And Sale Calculation

Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Net Intangibles Purchase And Sale for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DiaMedica Therapeutics Net Intangibles Purchase And Sale Related Terms

Thank you for viewing the detailed overview of DiaMedica Therapeutics's Net Intangibles Purchase And Sale provided by GuruFocus.com. Please click on the following links to see related term pages.

DiaMedica Therapeutics (DiaMedica Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DiaMedica Therapeutics Inc (NAS:DMAC) » Definitions » Net Intangibles Purchase And Sale
Comparable Companies
CLRB ORMP ARMP CLSD IOBT VIGL FGEN ANIX ELTX ALVR OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
301 Carlson Parkway, Suite 210, Minneapolis, MN, USA, 55305
Website
https://www.diamedica.com
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.
Executives
Jan Stahlberg 10 percent owner C/O TRILL INVEST AB, SVEAVAGEN 17 FL 18, STOCKHOLM V7 SE 111 57
Scott Kellen officer: CFO and Secretary 3405 ANNAPOLIS LANE, SUITE 200, MINNEAPOLIS MN 55447
Randall Michael Giuffre director 2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Ab Trill 10 percent owner SVEAVAGEN 17, 18TH FLOOR, STOCKHOLM V7 SE-11157
Richard D. Pilnik director 2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Dietrich John Pauls director, officer: President and CEO 2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Richard Ii Jacinto 10 percent owner 394 SADDLE BACK TRAIL, FRANKLIN LAKES NJ 07417
David J. Wambeke officer: Chief Business Officer 301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS MN 55305
Private Ab Tomeqt 10 percent owner C/O KINKON AB, BIBLIOTEKSGATAN 25, STOCKHOLM V8 11435
Koch Thomas Von 10 percent owner TOMENTERPRISE AB, BOX 5322, STOCKHOLM V7 102 47
Ab Tomenterprise 10 percent owner C/O EQT PARTNERS AB, BOX 16509, STOCKHOLM V7 103 27
Charles Pauling Semba director TWO CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Richard Kuntz director MEDTRONIC, INC., 710 MEDTRONIC PWKY MS LC 310, MINNEAPOLIS MN 55432
Tanya Lewis director C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVE., NEWTON MA 02459
Julie Vanorsdel Daves officer: SVP Clinical Development Oper. 301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS MN 55305